Trial was the first to test a drug meant to delay or halt mental decline in people who have a genetic predisposition
Medicare spending higher for adults with a formal clinical diagnosis of dementia versus a positive screening for cognitive impairment
Highest prevalence seen for high blood pressure and not meeting aerobic physical activity guidelines, followed by obesity
Larger volume associated with severity of cognitive impairment across Alzheimer disease spectrum
Risk factors differ based on sex and race and ethnicity
Individualized multidomain interventions equally effective for improving cognition in women, men
Presence of Alzheimer disease pathology related to Stages of Objective Memory Impairment in cognitively unimpaired older adults
Less than one-quarter of older adults report they would want to take it
Associations consistent across different psychiatric conditions, for Alzheimer disease and all other dementias
Announcement comes shortly after Aduhelm maker Biogen cut the price of the drug by about half, from $56,000 to $28,000 a year